136 related articles for article (PubMed ID: 38233985)
1. Carboplatin Dosing on the Basis of Renal Function: 30+ Years after Calvert.
Schwenk MH
Kidney360; 2024 Feb; 5(2):271-273. PubMed ID: 38233985
[No Abstract] [Full Text] [Related]
2. Comparison of two methods for carboplatin dosing in children with retinoblastoma.
Allen S; Wilson MW; Watkins A; Billups C; Qaddoumi I; Haik BH; Rodriguez-Galindo C
Pediatr Blood Cancer; 2010 Jul; 55(1):47-54. PubMed ID: 20486170
[TBL] [Abstract][Full Text] [Related]
3. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
4. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.
Shepherd ST; Gillen G; Morrison P; Forte C; Macpherson IR; White JD; Mark PB
Eur J Cancer; 2014 Mar; 50(5):944-52. PubMed ID: 24445148
[TBL] [Abstract][Full Text] [Related]
5. Misinterpretation of a Calvert-derived formula leading to carboplatin overdose in two children.
Liem RI; Higman MA; Chen AR; Arceci RJ
J Pediatr Hematol Oncol; 2003 Oct; 25(10):818-21. PubMed ID: 14528109
[TBL] [Abstract][Full Text] [Related]
6. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
[TBL] [Abstract][Full Text] [Related]
8. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
Donahue A; McCune JS; Faucette S; Gillenwater HH; Kowalski RJ; Socinski MA; Lindley C
Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
[TBL] [Abstract][Full Text] [Related]
9. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
Donadio C; Lucchesi A; Ardini M; Cosio S; Fanucchi A; Gadducci A
Ther Drug Monit; 2009 Feb; 31(1):63-9. PubMed ID: 19077927
[TBL] [Abstract][Full Text] [Related]
10. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
11. Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes.
Harris BDW; Phan V; Perera V; Szyc A; Galettis P; Martin JH; Walpole E; McLachlan AJ; Clarke SJ; Reuter SE; Charles KA
Clin Pharmacokinet; 2020 Aug; 59(8):1013-1026. PubMed ID: 32034726
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of carboplatin dosage based on 4-variable modification of diet in renal disease equation.
Barry A; O'Cearbhaill R; Griffin D; Donnellan P; Keane M; Grimes H
Ir J Med Sci; 2009 Sep; 178(3):301-7. PubMed ID: 19002550
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
Holweger K; Lipp HP; Beijnen JH; Bokemeyer C; Hartmann JT
Cancer Chemother Pharmacol; 2011 Sep; 68(3):693-701. PubMed ID: 21136060
[TBL] [Abstract][Full Text] [Related]
14. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.
Thomas H; Boddy AV; English MW; Hobson R; Imeson J; Lewis I; Morland B; Pearson AD; Pinkerton R; Price L; Stevens M; Newell DR
J Clin Oncol; 2000 Nov; 18(21):3614-21. PubMed ID: 11054434
[TBL] [Abstract][Full Text] [Related]
15. Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance.
White-Koning M; Paludetto MN; Le Louedec F; Gladieff L; Chevreau C; Chatelut E; Puisset F
Cancer Chemother Pharmacol; 2020 Mar; 85(3):585-592. PubMed ID: 31915969
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin dosing for adult Japanese patients.
Ando Y; Shimokata T; Yasuda Y; Hasegawa Y
Nagoya J Med Sci; 2014 Feb; 76(1-2):1-9. PubMed ID: 25129986
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer.
Hiraike M; Hiraki Y; Misumi N; Hanada K; Tsuji Y; Kamimura H; Karube Y; Kashiwabara K
Cancer Chemother Pharmacol; 2012 Mar; 69(3):845-8. PubMed ID: 22194156
[TBL] [Abstract][Full Text] [Related]
18. Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function.
Adamson PC; Veal GJ; Womer RB; Meany HJ; Bernhardt MB; Frazier AL; Balis FM
Pediatr Blood Cancer; 2019 Jun; 66(6):e27672. PubMed ID: 30767382
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of calculating carboplatin dosage using Japanese equation for estimating GFR for gynecologic cancer].
Kidera Y; Nakao M; Tsubaki M; Yoshinaga M; Kajitani F; Yanae M; Sakano M; Yamazoe Y; Chiba Y; Moriyama K; Nishida S
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1143-8. PubMed ID: 21772099
[TBL] [Abstract][Full Text] [Related]
20. Safety and Survival Outcomes in Lung Cancer Patients Receiving Carboplatin: Impact of Uncapped Dosage.
Le Bozec A; Boulanger C; Mongaret C; Maréchal A; Dewolf M; Slimano F
Chemotherapy; 2021; 66(3):72-77. PubMed ID: 34280922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
